News & Events

1 09, 2024

Immunogenicity of Botulinum Toxin A: Insights

2024-09-01T00:00:00+00:00

BACKGROUND: Botulinum toxin A (BoNT-A) is widely used in treating dystonia and spasticity to managing chronic migraine and cosmetic applications. However, its immunogenic potential presents challenges, such as the development of neutralizing antibodies that lead to diminished therapeutic efficacy over time, known as secondary nonresponse. OBJECTIVE: This review aims to bridge the knowledge gap regarding [...]

Immunogenicity of Botulinum Toxin A: Insights2024-09-01T00:00:00+00:00
22 08, 2024

First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

2024-08-22T00:00:00+00:00

Toll-like receptor (TLR)7 is a pattern recognition receptor that critically contributes to the pathogenesis of systemic lupus erythematosus (SLE). DS-7011a is an anti-TLR7 monoclonal antibody that prevents TLR7 from signaling. The aim of this first-in-human, double-blind, randomized, and placebo-controlled study was to evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of single ascending intravenous (IV) and [...]

First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus2024-08-22T00:00:00+00:00
20 08, 2024

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England

2025-10-06T21:52:07+00:00

Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel. Exa-cel is the world’s first CRISPR-based gene therapy and the first gene therapy available in Europe for treating severe beta-thalassaemia...

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England2025-10-06T21:52:07+00:00
6 08, 2024

FDA Approves First T Cell Receptor (TCR) Gene Therapy

2025-10-06T21:50:09+00:00

Tecelra is the first FDA-approved T cell receptor (TCR) gene therapy. The product is an autologous T cell immunotherapy composed of a patient’s own T cells. T cells in Tecelra are modified to express a TCR that targets MAGE-A4, an antigen expressed by cancer cells in synovial sarcoma...

FDA Approves First T Cell Receptor (TCR) Gene Therapy2025-10-06T21:50:09+00:00
31 07, 2024

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL

2025-10-06T21:48:21+00:00

Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period, according to a recent study...

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL2025-10-06T21:48:21+00:00
13 05, 2024

American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference – 2024

2025-06-24T14:26:24+00:00

Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]

American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference – 20242025-06-24T14:26:24+00:00
7 05, 2024

American Society of Gene and Cell Therapy (ASGCT) Conference – 2024

2025-10-06T21:50:18+00:00

Avance Biosciences™ is excited to announce our participation in the American Society of Gene & Cell Therapy (ASGCT) conference, where we’ll be showcasing our advanced services and expertise to propel the future of gene and cell therapy. [...]

American Society of Gene and Cell Therapy (ASGCT) Conference – 20242025-10-06T21:50:18+00:00
6 05, 2024

Workshops on Recent Issues in Bioanalysis (WRIB) Conference – 2024

2025-06-24T14:26:24+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Workshops on Recent Issues in Bioanalysis (WRIB) Conference – 20242025-06-24T14:26:24+00:00
3 04, 2024

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy

2025-10-06T21:48:26+00:00

CAR T-cell therapies show promise for blood cancers but struggle with solid tumors due to T-cell weakness in tumor microenvironments. Researchers find genetic alterations in cancerous T cells, giving engineered T cells "superpowers" to effectively kill tumors without behaving like cancer cells...

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy2025-10-06T21:48:26+00:00
Go to Top